Pascal Nizet

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. We focus in two conditions in which patients suffer from vision impairment and blindness, paralysis and even death: acute optic neuritis and neuromyelitis optica. Our lead candidate ACT01 (BN201) is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and the product is now in clinical Phase 2 (study ACUITY) in France. With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

Laboratorios Asderco is a dynamic, privately-owned company dedicated to skin care and skin disorders that develops and commercializes branded differentiated products for patients in America and Europe through own structure or strategic partners. Laboratorios Asderco markets a portfolio of products for the relief of symptomatology and/or cure of common and rare dermatologic diseases. Our first product, Transkur, an antiperspirant, has been launched in Spain by our partner @Caestus in September 2022

Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. We focus in two conditions in which patients suffer from vision impairment and blindness, paralysis and even death: acute optic neuritis and neuromyelitis optica. Our lead candidate ACT01 (BN201) is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and the product is now in clinical Phase 2 (study ACUITY) in France. With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.

Pharmaphenix is a boutique international pharmaceutical consulting company specialized in all aspects of the Business Development chain. Our clients include a broad range of biotechnology companies, start-up ventures, investors and pharmaceutical companies. Our focus is on the rapidly emerging markets of Asia Pacific, Latin America and Middle East-Africa. Our people’s deep corporate experience enables us leveraging on our international knowledge and relationships to get a global reach with a contact base that includes key players in our focus markets. Pharmaphenix is also Core Member of the GHN (Global Healthcare Network)